|
Mar 13
|
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
|
|
Feb 24
|
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
|
|
Jul 8
|
REVB Releases Positive Test Results—Potential Catalyst
|
|
Jun 24
|
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
|
|
Jun 24
|
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
|
|
Feb 5
|
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
|
|
Feb 1
|
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
|
|
Jan 30
|
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
|
|
Oct 4
|
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
|
|
Oct 2
|
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
|